2-[(N,N-diethyl-glycyl)-amino]-4-methyl-5-(2-methylsulfanyl-ethyl)-pyrrole-3-carboxylic acid amide | 72406-70-3

• 英文名称: 2-[(N,N-diethyl-glycyl)-amino]-4-methyl-5-(2-methylsulfanyl-ethyl)-pyrrole-3-carboxylic acid amide
• 英文别名: 2-[[2-(diethylamino)acetyl]amino]-4-methyl-5-(2-methylsulfanylethyl)-1H-pyrrole-3-carboxamide
• CAS: 72406-70-3
• 化学式: C₁₅H₂₆N₄O₂S
• 分子量: 326.463
• InChiKey: SKMNLAURQAUAMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(N,N-diethyl-glycyl)-amino]-4-methyl-5-(2-methylsulfanyl-ethyl)-pyrrole-3-carboxylic acid amide 、 盐酸 以84%的产率得到
  参考文献：
  名称：

  JOHNSON R. W.; KEENAN T. H.; KOSH J. W.; SOWELL J. W., J. PHARM. SCI., 1979, 68, NO 8, 955-958

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-chloro-acetylamino)-4-methyl-5-(2-methylsulfanyl-ethyl)-pyrrole-3-carboxylic acid amide 、 二乙胺 以93%的产率得到
  参考文献：
  名称：

  JOHNSON R. W.; KEENAN T. H.; KOSH J. W.; SOWELL J. W., J. PHARM. SCI., 1979, 68, NO 8, 955-958

  摘要：

  DOI：

文献信息

• Methods and compositions for the treatment of cancer cachexia
  申请人：Ohio State Innovation Foundation

  公开号：US11529323B2

  公开（公告）日：2022-12-20

  In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

  在一个方面，本公开涉及治疗癌症恶病质的方法和组合物。在另一个方面，组合物是一种药物组合物，包含I/IIB类HDAC抑制剂和雄激素。在更进一步的方面，治疗方法包括向已被诊断为癌症恶病质的受试者或患者施用I/IIB类HDAC抑制剂和雄激素。在某些方面，I/IIB类HDAC抑制剂是一种称为AR-42的化合物。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA
  申请人：Ohio State Innovation Foundation

  公开号：US20200289438A1

  公开（公告）日：2020-09-17

  In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA CACHEXIE CANCÉREUSE
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2019055687A1

  公开（公告）日：2019-03-21

  In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class l/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class l/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class l/IIB HDAC inhibitor is a compound known as AR-42.